SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand.

COVID-19 Cancer Household caregiver SARS-CoV-2 Seroprevalence Thailand

Journal

Public health in practice (Oxford, England)
ISSN: 2666-5352
Titre abrégé: Public Health Pract (Oxf)
Pays: England
ID NLM: 101774776

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 19 07 2022
revised: 13 10 2022
accepted: 02 11 2022
entrez: 14 11 2022
pubmed: 15 11 2022
medline: 15 11 2022
Statut: ppublish

Résumé

Patients with cancer may be at an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and experience more severe outcomes. Low vaccine coverage in the early phase of the coronavirus disease 2019 (COVID-19) pandemic meant that personal and social measures to reduce viral spread were the only methods of lowering the risk of infection among cancer patients. This study explored the prevalence of SARS-CoV-2 antibodies in cancer patients and caregivers in a cancer hospital after the second COVID-19 outbreak in Thailand. Cross-sectional study. A SARS-CoV-2 seroprevalence cross-sectional survey was conducted among 200 cancer patients and 200 household caregivers in a tertiary cancer care hospital in Bangkok, Thailand. The survey took place between 4 March and May 31, 2021 - a time period covering the end of the second COVID-19 wave and the early phase of the third wave in Thailand. Rigorous personal and social measures to reduce viral spread among cancer patients and caregivers lead to an extremely low prevalence of SARS-CoV2 infection (0% among cancer patients and 1% among household caregivers). This study demonstrates the importance of social distancing and personal hygiene measures for the prevention of SARS-CoV-2 infection, even when vaccine coverage is low.

Identifiants

pubmed: 36373034
doi: 10.1016/j.puhip.2022.100341
pii: S2666-5352(22)00117-3
pmc: PMC9637045
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100341

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS One. 2022 Apr 27;17(4):e0263316
pubmed: 35476709
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
JAMA Netw Open. 2022 Apr 1;5(4):e229317
pubmed: 35482308
ESMO Open. 2020 Sep;5(5):e000889
pubmed: 32878898
IJID Reg. 2021 Dec;1:1-2
pubmed: 35721778
J Popul Res (Canberra). 2022;39(4):567-588
pubmed: 34776786
BMJ. 2021 Nov 17;375:e068302
pubmed: 34789505
J Infect Public Health. 2022 Apr 29;15(6):609-614
pubmed: 35537237
J Med Virol. 2022 Mar;94(3):1060-1066
pubmed: 34704620
Cancer Treat Rev. 2020 Nov;90:102102
pubmed: 32947121

Auteurs

Teerapat Ungtrakul (T)

Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.

Gaidganok Sornsamdang (G)

Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.

Kamonwan Soonklang (K)

Chulabhorn Learning and Research Center, Chulabhorn Royal Academy, Bangkok, Thailand.

Siriporn Saeloo (S)

Chulabhorn Learning and Research Center, Chulabhorn Royal Academy, Bangkok, Thailand.

Kasiruck Wittayasak (K)

Chulabhorn Learning and Research Center, Chulabhorn Royal Academy, Bangkok, Thailand.

Ornpreya Suptawiwat (O)

Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.

Rojjanaporn Pulmanausahakul (R)

Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.

Nanthida Phattraprayoon (N)

Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.

Chirayu Auewarakul (C)

Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.

Nithi Mahanonda (N)

Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.

Classifications MeSH